NEW DATA SHOW ORAL FERRIC MALTOL (FERACCRU®) MAY BE A COST-EFFECTIVE ALTERNATIVE TO INTRAVENOUS (IV) CARBOXYMALTOSE WITH AT LEAST AS GREAT BENEFITS IN THE QUALITY OF LIFE OF PATIENTS WITH IRON DEFICIENCY ANAEMIA (IDA) AND INFLAMMATORY BOWEL DISEASE (IBD)
19 February 2020
NORGINE B.V. ENTERS INTO EXCLUSIVE LICENCE AND DISTRIBUTION AGREEMENTS FOR THE COMMERCIALISATION OF PLENVU® IN A NUMBER OF COUNTRIES IN LATIN AMERICA, SOUTHERN AFRICA, CENTRAL AND EASTERN EUROPE
12 February 2020
We are a leading European specialist pharmaceutical company with over 110 years’ heritage. We have a presence in all major European markets and employ over 1,300 people. We operate a well-established European infrastructure to develop, manufacture and commercialise products.
What sets us apart from other companies is our flexible and agile approach to partnering and collaboration. We are able to integrate new products quickly for the benefit of healthcare systems and patients in Europe, Australia and New Zealand.
We are headquartered in the Netherlands.
Peter Stein, CEO
Our core values of One Norgine, Innovation and Trustworthiness underpin all of our activities. They are fundamental to achieving our vision.
We operate consistently throughout Norgine at all times, while remaining sensitive to local practices and cultural differences
We are flexible and agile and we look at new and better ways of working to make sure we continue to bring benefit for healthcare professionals, payers and patients in order to generate a financial return
We are patient centric and we act fairly, ethically and openly at all times